Payment overview · 2025
General Payments
$72,215.94
149 reported records · 13 companies
Healthcare provider profile · identity verified
Stephen P Chen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MONTEREY PARK, CA · NPI 1205821477
Verified facts
What the public records show
CMS Open Payments records show Stephen P Chen, MD received $72,215.94 in general payments during 2025 across 149 reported records.
AstraZeneca Pharmaceuticals LP accounted for 72.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Nucala, Ofev.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 563 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Adempas by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52,330.84 | 72.5% | 64 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14,709.21 | 20.4% | 34 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $2,714.78 | 3.8% | 15 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $1,437.09 | 2.0% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $318.46 | 0.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $221.61 | 0.3% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $128.42 | 0.2% | 5 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $126.22 | 0.2% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $112.30 | 0.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.56 | 0.1% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $31.69 | 0.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.03 | 0.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $19.73 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $63,092.50 | 29 |
| Food and Beverage | $4,832.92 | 98 |
| Honoraria | $2,000.00 | 1 |
| Travel and Lodging | $1,334.42 | 18 |
| Education | $491.10 | 2 |
| Consulting Fee | $465.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $51,967.43 | 56 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14,144.63 | 14 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $2,714.78 | 15 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $1,437.09 | 5 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $564.58 | 20 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $278.33 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $241.58 | 7 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $221.61 | 11 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $217.78 | 10 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $194.15 | 8 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $157.51 | 7 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $132.03 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $126.22 | 3 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $126.22 | 3 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.80 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.38 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.56 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $41.08 | 2 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $40.13 | 2 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $31.69 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
563 | 104 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 621 | 134 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 563 | 104 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 465 | 116 |
| Fluticasone Propionate | Fluticasone Propionate | 388 | 103 |
| Roflumilast | Roflumilast | 339 | 58 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 258 | 50 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 203 | 48 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 186 | 50 |
| Breo Ellipta | Fluticasone/Vilanterol | 174 | 28 |
| Lorazepam | Lorazepam | 162 | 28 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 150 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 140 | 33 |
| Prednisone | Prednisone | 138 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 30 |
| Omeprazole | Omeprazole | 87 | 23 |
| Furosemide | Furosemide | 86 | 25 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 84 | 15 |
| Jardiance | Empagliflozin | 83 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 15 |
| Amlodipine Besylate | Amlodipine Besylate | 78 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 72 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 71 | 16 |
| Gabapentin | Gabapentin | 69 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 12 |
| Azelastine Hcl | Azelastine Hcl | 66 | 13 |
| Losartan Potassium | Losartan Potassium | 66 | 13 |
| Creon | Lipase/Protease/Amylase | 65 | 14 |
| Levofloxacin | Levofloxacin | 58 | 37 |
| Spiriva Handihaler | Tiotropium Bromide | 56 | suppressed |
| Potassium Chloride | Potassium Chloride | 55 | 12 |
| Atorvastatin Calcium | Atorvastatin Calcium | 54 | suppressed |
| Clonazepam | Clonazepam | 52 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 11 |
| Azithromycin | Azithromycin | 49 | 29 |
| Eliquis | Apixaban | 49 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 47 | 20 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 45 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 38 | suppressed |
| Restasis | Cyclosporine | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Simvastatin | Simvastatin | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 35 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 34 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 31 | suppressed |
| Pentoxifylline | Pentoxifylline | 31 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | suppressed |
| Adempas | Riociguat | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Ofev | Nintedanib Esylate | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Metformin Hcl | Metformin Hcl | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Ambrisentan | Ambrisentan | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 22 | 17 |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Neupro | Rotigotine | 18 | suppressed |
| Fasenra Pen | Benralizumab | 17 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 17 | 14 |
| Allopurinol | Allopurinol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Voriconazole | Voriconazole | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | 11 |
| Celecoxib | Celecoxib | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nucala | Mepolizumab | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Rifabutin | Rifabutin | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $72,215.94 · 149 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, AVYCAZ, BREZTRI, DALVANCE, DUPIXENT, EMBLAVEO, JARDIANCE, JASCAYD, MOUNJARO, NUCALA, OFEV, OPSUMIT, Ohtuvayre, Ozempic, Rybelsus, SHINGRIX, TEFLARO, TEZSPIRE, Tyvaso, UPTRAVI, WINREVAIR, YUPELRI, ZEPBOUND, ZERBAXA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error